NCPA CEO Doug Hoey was one of 10 witnesses invited to speak at a hearing, "Examining the Drug Supply Chain," on Capitol Hill Wednesday. The hearing was called by the Committee on Energy and Commerce Subcommittee on Health.
Hoey spoke about the need for increased transparency with PBM rebates and spread pricing, generic drug reimbursement, and pharmacy DIR fees. He also said that "systemic barriers" must be overcome.
"It makes financial sense for Congress to demand increased true transparency into the prescription drug marketplace for all taxpayer-funded prescription drugs and to fully utilize the expertise of the community pharmacist to identify potential savings," Hoey told the committee.
Watch the hearing here. Hoey's remarks begin at 53:21.
Print Page
Email to a Friend